Celebrating its 5th edition, the B2B Uro-Oncology: GU Cancers Triad meeting returns to the 43rd Annual Congress in Istanbul, Türkiye, on Friday, October 13, 2023, for a full in-person programme, showcasing the latest innovations in uro-oncology. View the programme agenda here.
About the B2B Uro-Oncology: GU Cancers Triad
The rapidly evolving treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists, medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians need to keep up with new data on therapeutic options, provide individualized care through a multidisciplinary approach, and use optimal treatment sequence or combinations while effectively managing side effects.
Aiming to support the educational needs of urologists and allied healthcare practitioners, the B2B Uro-Oncology: GU Cancers Triad meeting will feature multidisciplinary, scientific, and educational sessions highlighting cutting-edge content in management of the most prevalent GU malignancies: prostate, bladder, and kidney cancers. Through state-of-the-art presentations, timely debates, and interactive panel discussions, world-renowned experts in GU oncology will:
At the end of this programme, participants will be able to:
The 5th B2B Uro-Oncology: GU Cancers meeting will be transmitted live on SIU@U and webcasts will also be made available on-demand. Keep the conversation going by sharing your thoughts and questions with colleagues on social media using #B2BGUCancersTriad
Available now, the full Programme Agenda for review.